Article Text

Download PDFPDF
Role of thuja in the management of laryngeal papilloma
  1. Shivagamasundari Murali1,
  2. Prasanna Kumar Saravanam2 and
  3. Nethra Dinakaran3
  1. 1ENT, Head and Neck Surgery, Sri Ramachandra Medical College and Research Institute, Chennai, India
  2. 2ENT, Head and Neck Surgery, Sri Ramachandra University Medical College, Chennai, India
  3. 3Otorhinolaryngology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India
  1. Correspondence to Dr Prasanna Kumar Saravanam; sprasannakumar10{at}


Juvenile respiratory laryngeal papillomatosis is a subset of a larger clinical entity of recurrent respiratory papillomatosis. It is characterised by the development of recurrent papillomata in the vocal folds. Human papillomavirus types 6 and 11 has been implicated to be the most common strain of virus associated with the formation of laryngeal papilloma. Clinical diagnosis is based on typical appearance of warty lesion on endoscopy. Surgery is the primary line of management along with adjuvant therapy like antiviral drugs and immunomodulators. Thuja occidentalis is a tree native to North America whose leaves and leaf oil have antiviral, antibacterial and antifungal properties. It has been widely used for the treatment of condylomatous skin lesions and warts. Here we discuss the outcome of thuja as an adjuvant therapy in the treatment of laryngeal papillomatosis in an 8-year-old child.

  • ear
  • nose and throat
  • human papilloma virus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors I, ND have written the case report. SM has contributed and helped with designing the case report. Professor PKS has dealt with the case.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.